Loading…
Senti Biosciences Holdings, Inc. is projected to decline to $0.3335 by 2027, a -10% move from its current price of $0.3701. SNTI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.3463 | $0.3698 | $0.3949 | -0.08% |
| Aug 6 | $0.3367 | $0.3695 | $0.4055 | -0.16% |
| Aug 7 | $0.3294 | $0.3692 | $0.4138 | -0.24% |
| Aug 8 | $0.3234 | $0.3689 | $0.4208 | -0.32% |
| Aug 9 | $0.3182 | $0.3686 | $0.427 | -0.40% |
| Aug 10 | $0.3135 | $0.3683 | $0.4327 | -0.48% |
| Aug 11 | $0.3092 | $0.368 | $0.438 | -0.57% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3092 | $0.368 | $0.438 | -0.57% |
| Week 2 | $0.2861 | $0.3659 | $0.4681 | -1.13% |
| Week 3 | $0.2691 | $0.3639 | $0.4919 | -1.69% |
| Week 4 | $0.2554 | $0.3618 | $0.5125 | -2.24% |
| Week 5 | $0.2438 | $0.3598 | $0.5309 | -2.80% |
| Week 6 | $0.2335 | $0.3577 | $0.5479 | -3.34% |
| Week 7 | $0.2244 | $0.3557 | $0.5638 | -3.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Senti Biosciences Holdings, Inc. is a clinical stage biotechnology company that develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead approach uses off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies for oncology indications with unmet need.
The company offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. The company also develops platforms to identify tumor-associated antigens and NOT GATE candidates, and its pipeline includes preclinical programs and partnered programs related to cell therapies for regenerative medicines. Senti Biosciences changed its name to Senti Biosciences Holdings, Inc.
in April 2026 after formerly being known as Senti Biosciences, Inc. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
The asset operates in the Healthcare category and remains focused on developing and commercializing cell and gene therapies in oncology and related fields. It has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd.
and has evolved its branding and corporate structure since its inception, reflecting its ongoing clinical stage activities and pipeline development.
Senti Biosciences Holdings, Inc. (SNTI) is currently priced at $0.347 per share with a market capitalization of $10.81M, and it ranks 5067 by market cap. The stock trades in the healthcare/biotech space, reflecting its clinical stage focus and pipeline-related activities.
The current price sits near the lower end of its 30-day range and amid a neutral near-term technical profile, with a long-run forecast showing mixed near-term performance but meaningful upside by 2030 and beyond.
Forecasts show a path from flat-to-modest current pricing in 2026 toward stronger upside in the 2030s and 2040s, culminating in substantial longer-term gains by 2050. Near-term years display mixed outcomes, while longer-horizon years point to higher average prices and positive ROI, underscoring a potential multi-year rebound as development progresses.
A major floor 7.9% below — a decisive break under it would weaken the trend.
The nearest floor, 7.9% below — buyers have tended to step in here.
The nearest ceiling, 199.9% above — a clean break opens room to run.
A major ceiling 269.2% above — clearing it would confirm fresh momentum.
Key SNTI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNTI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.3608 | Buy | $0.3669 | Buy |
| MA 10 | $0.397 | Sell | $0.4299 | Sell |
| MA 20 | $0.6269 | Sell | $0.5668 | Sell |
| MA 50 | $0.8472 | Sell | $0.7612 | Sell |
| MA 100 | $0.8991 | Sell | $0.8979 | Sell |
| MA 200 | $1.16 | Sell | $1.19 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 21.12 | Buy |
| Stoch RSI (14) | 4.21 | Buy |
| CCI (20) | -70.60 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -41.51 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.47 | Sell |
| Awesome (5,34) | -0.43 | Sell |
| Ultimate (7,14,28) | 14.25 | Buy |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 0.34 | Buy |
| ADX (14) | 39.00 | Sell |
| ATR (14) | 0.04 | Info |
30-day technical picture: sentiment is NEUTRAL. The RSI(14) stands at 20, indicating subdued momentum within a framework where sentiment remains neutral. The 50-day simple moving average is $0.8696 and the 200-day simple moving average is $1.18, both above the current price of $0.347, suggesting near-term underperformance versus longer-term benchmarks.
Key support is at $0.347 and resistance at $1.11. The 30-day price range stretches from $0.2207 to $0.5456, highlighting potential for modest upside but with a relatively wide band of activity. The stock exhibits an annualized volatility of 100%, reflecting substantial variability in price movement over the year.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.341 | $0.3701 | $0.4894 | 0% | Neutral | |
| $0.243 | $0.3335 | $0.4946 | -10% | Neutral | |
| $0.1982 | $0.2893 | $0.4578 | -22% | Bearish | |
| $0.218 | $0.3353 | $0.5574 | -9% | Neutral | |
| $0.2825 | $0.4557 | $0.789 | +23% | Bullish | |
| $0.276 | $0.4654 | $0.8343 | +26% | Bullish | |
| $0.2633 | $0.463 | $0.8561 | +25% | Bullish | |
| $0.2292 | $0.4198 | $0.798 | +13% | Neutral | |
| $0.206 | $0.3926 | $0.7651 | +6% | Neutral | |
| $0.2158 | $0.4274 | $0.8524 | +15% | Neutral | |
| $0.2512 | $0.5583 | $1.22 | +51% | Bullish | |
| $0.5152 | $1.14 | $2.63 | +209% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.341 | $0.3701 | $0.4646 | +0.00% |
| September 2026 | $0.2926 | $0.3557 | $0.4511 | -3.89% |
| October 2026 | $0.2789 | $0.3437 | $0.4448 | -3.36% |
| November 2026 | $0.2922 | $0.3642 | $0.479 | +5.96% |
| December 2026 | $0.2912 | $0.3668 | $0.4894 | +0.70% |
Click any year to see its month-by-month SNTI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SNTI price prediction for 2026 points to an average of $0.3701 (low $0.341, high $0.4894) — a potential gain of 0% on today's $0.3701. A consolidation phase looks the most probable path here.
In 2027, SNTI is projected to trade between $0.243 and $0.4946, averaging $0.3335 — a potential decline of -10% from today's $0.3701. That is -10% versus the projected 2026 average. Price action looks broadly range-bound.
Senti Biosciences Holdings, Inc.'s 2028 outlook centres on $0.2893, within a $0.1982 to $0.4578 range. That is -13% versus the projected 2027 average. That marks a -22% change versus current levels. Expect choppier, lower action through this leg of the cycle.
By 2029, SNTI could reach as high as $0.5574, with a base case around $0.3353 and support toward $0.218 — roughly -9% from $0.3701. Price action looks broadly range-bound.
Expect SNTI to range from $0.2825 to $0.789 through 2030. The $0.4557 average target implies a +23% move from current prices. That is up +36% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The SNTI price prediction for 2031 points to an average of $0.4654 (low $0.276, high $0.8343) — a potential gain of +26% on today's $0.3701. Momentum favours further upside here.
In 2032, SNTI is projected to trade between $0.2633 and $0.8561, averaging $0.463 — a potential gain of +25% from today's $0.3701. That is -1% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Senti Biosciences Holdings, Inc.'s 2033 outlook centres on $0.4198, within a $0.2292 to $0.798 range. That is -9% versus the projected 2032 average. That marks a +13% change versus current levels. Price action looks broadly range-bound.
By 2034, SNTI could reach as high as $0.7651, with a base case around $0.3926 and support toward $0.206 — roughly +6% from $0.3701. A consolidation phase looks the most probable path here.
Expect SNTI to range from $0.2158 to $0.8524 through 2035. The $0.4274 average target implies a +15% move from current prices. That is up +9% on the projected 2034 average. Price action looks broadly range-bound.
The SNTI price prediction for 2040 points to an average of $0.5583 (low $0.2512, high $1.22) — a potential gain of +51% on today's $0.3701. Buyers look set to stay in control over this stretch.
In 2050, SNTI is projected to trade between $0.5152 and $2.63, averaging $1.14 — a potential gain of +209% from today's $0.3701. That is up +105% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SNTI today (≈ 2,701.97244 SNTI) could be worth
$3,093.36
+$2,093.36 (+209%) by 2050 · US Dollar
Based on the average projected SNTI price of $1.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNTIwould be worth at today's price.
$1,000 invested in SNTI on Jul 31, 2025 (≈ 588.235278 SNTI) would be worth
$217.71
-$782.29 (-78.2%) today · 0.22× · US Dollar
Based on a SNTI entry price of $1.7 vs. today's $0.3701.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.404 | $916.09 | -8.4% |
| 1 month ago | $1.06 | $349.15 | -65.1% |
| 3 months ago | $1.02 | $362.84 | -63.7% |
| 6 months ago | $1.01 | $366.44 | -63.4% |
| 1 year ago | $1.7 | $217.71 | -78.2% |
| All time (5.0y) ago | $97.9 | $3.78 | -99.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNTI forecast.
Our base-case forecast reaches $0.74 around 2050.
Implied market cap at $0.74: $23.05M
Multi-year forecasts show a bullish tilt emerging after a flat to downbeat near term. For 2030, the average price is projected at $0.4284 with a 23.5% ROI and a bullish sentiment. The 2040 forecast extends the upside, with an average of $0.5267 and a 51.8% ROI, maintaining a bullish stance.
By 2050, the model envisions an average price of $1.07 with a 207.4% ROI and a bullish outlook, signaling meaningful appreciation from current levels if the trajectory unfolds. The forecast also highlights near-term pressure in 2027–2029, where average prices range from about $0.3097–$0.3126 and ROIs dip into negative territory (-10.8%, -20.6%, -9.9%), before turning more favorable in 2030 and beyond. These are estimates, not guarantees, and reflect potential outcomes given the listed inputs and market dynamics.
Drivers and risks are tied to the path of clinical development, regulatory milestones, and the broader biotech funding environment, all of which influence long-horizon pricing patterns and investor sentiment. The outlook remains contingent on future developments and market conditions, and actual results may differ from the stated projections.
Tap a question to reveal the answer.
2030 forecast: avg $0.4284 with a 23.5% ROI, sentiment BULLISH. The 2030 min is $0.2655 and the max is $0.7421.
Near term shows flat to negative momentum with 2026 min/avg/max of $0.347/$0.347/$0.4553 and ROI 0; 2027 ROI -10.8%; 2028 ROI -20.6%; 2029 ROI -9.9%. Longer term, 2030 shows a bullish outlook with avg $0.4284 and ROI 23.5%. The 2040 and 2050 forecasts are bullish with avg $0.5267 and $1.07 and ROIs of 51.8% and 207.4% respectively.
Yes. The 2040 max is $1.16 and the 2050 max is $2.45, indicating that surpassing $1 is possible by 2040 in the max scenario. Near-term max values stay below $1 until the 2040 horizon.
Current price is $0.347 and market cap is $10.81M.
For 2050, the forecast shows min $0.4799, avg $1.07, max $2.45 with a ROI of 207.4%, and sentiment BULLISH.
Senti Biosciences Holdings, Inc. Community Discussion
0Share your Senti Biosciences Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.